# Shenzhen Geno-Immune Medical Institute: Phase 2 study withdrawn (Lung Cancer, NSCLC)

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | Shenzhen Geno-Immune Medical Institute |
| Sponsor type | Academic and hospital |
| Study | Intervention of Engineered Immune Effector T Cells Against Lung Cancer |
| NCT ID | NCT03353428 |
| Phase | Phase 2 |
| Status | withdrawn |
| Conditions | Lung Cancer; NSCLC |
| Intervention types | biological |
| Site countries | China |
| Posted | 2017-11-27 |
| Planned start | 2017-11-15 |
| Event | Withdrawn before enrolling |
| Event date | 2026-11-03 |
| Last update posted | 2026-11-03 |

## Why this score
- Posted in the last two weeks.
- Stopped early: budget and sites freed up.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT03353428). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.